CFRXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CFRXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), ContraFect's share price is $0.0151. ContraFect's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $-0.54. Hence, ContraFect's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for ContraFect's Price-to-Tangible-Book or its related term are showing as below:
During the past 11 years, ContraFect's highest Price to Tangible Book Ratio was 21.92. The lowest was 1.81. And the median was 4.60.
A closely related ratio is called PB Ratio. As of today, ContraFect's share price is $0.0151. ContraFect's Book Value per Sharefor the quarter that ended in Sep. 2023 was $-0.54. Hence, ContraFect's P/B Ratio of today is .
The historical data trend for ContraFect's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContraFect Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 21.92 | 6.12 | 11.13 | 2.10 | - |
ContraFect Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, ContraFect's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ContraFect's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where ContraFect's Price-to-Tangible-Book falls into.
ContraFect's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2023 ) |
= | 0.0151 | / | -0.538 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of ContraFect's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Lishan Aklog | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
Michael Messinger | officer: VP Finance | 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534 |
Cary Sucoff | director | 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904 |
David N. Low | director | EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Lisa Ricciardi | director | C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
Joshua B Muntner | officer: SVP Business Development | 30 FIFTH AVENUE, 12F, NEW YORK NY 10011 |
Shanghai Fosun Pharmaceutical (group) Co., Ltd. | 10 percent owner | BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233 |
Fosun Industrial Co., Ltd | 10 percent owner | FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000 |
Cara M Cassino | officer: Chief Medical Officer | 757 STONY POINT ROAD, BENSON VT 05743 |
Natalie Bogdanos | officer: General Counsel | 207-23 DARREN DRIVE, BAYSIDE NY 11360 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael J. Otto | director | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-06-2022
By Value_Insider Value_Insider • 12-19-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By PurpleRose PurpleRose • 07-14-2022
By sperokesalga sperokesalga • 06-20-2023
By PRNewswire PRNewswire • 02-27-2023
By Value_Insider Value_Insider • 11-28-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By Marketwired • 10-16-2023
By sperokesalga sperokesalga • 04-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.